CDoT is disease area agnostic, guided by the highest quality science-driven therapeutic hypotheses from the Broad PI community. Thanks to CDoT’s position within the Broad Institute, the rationale for projects accepted into the CDoT portfolio draws from a deep understanding of the genetics of specific human disease. 

CDoT is currently working in the disease areas of oncology, cardiovascular, immunoregulation,  psychiatry, kidney disease and type 2 diabetes. CDoT is involved in projects that span all stages of the drug discovery process.